Home Carboxys 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid

2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid

CAS No.:
68302-57-8
Catalog Number:
AG00333Z
Molecular Formula:
C16H14N2O4
Molecular Weight:
298.2934
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1g
98%
In Stock USA
United States
$38
- +
5g
98%
In Stock USA
United States
$100
- +
25g
98%
In Stock USA
United States
$300
- +
100g
98%
In Stock USA
United States
$850
- +
Product Description
Catalog Number:
AG00333Z
Chemical Name:
2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid
CAS Number:
68302-57-8
Molecular Formula:
C16H14N2O4
Molecular Weight:
298.2934
MDL Number:
MFCD00864790
IUPAC Name:
2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid
InChI:
InChI=1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21)
InChI Key:
SGRYPYWGNKJSDL-UHFFFAOYSA-N
SMILES:
CC(c1ccc2c(c1)c(=O)c1c(o2)nc(c(c1)C(=O)O)N)C
UNII:
BRL1C2459K
Properties
Complexity:
467  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
298.095g/mol
Formal Charge:
0
Heavy Atom Count:
22  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
298.298g/mol
Monoisotopic Mass:
298.095g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
103A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.1  
Literature
Title Journal
An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice. Nature medicine 20130301
Neuron-specific non-classical release of prothymosin alpha: a novel neuroprotective damage-associated molecular patterns. Journal of neurochemistry 20121001
Amlexanox is as effective as dexamethasone in topical treatment of erosive oral lichen planus: a short-term pilot study. Oral surgery, oral medicine, oral pathology and oral radiology 20120501
Development of a measure to assess effective listening and interactive communication skills in the delivery of children's rehabilitation services. Disability and rehabilitation 20120101
New Evidence-Based Treatment Approach in Behçet's Disease. Pathology research international 20120101
Clinical inquiry. What is the most effective way to treat recurrent canker sores? The Journal of family practice 20111001
Topical immunomodulators for management of oral mucosal conditions, a systematic review; Part II: miscellaneous agents. Expert opinion on emerging drugs 20110301
Nicolaus Copernicus: not only a great astronomer but also a physician. Journal of nephrology 20110101
Variable initial swing side and prolonged double limb support represent abnormalities of the first three steps of gait initiation in patients with Parkinson's disease with freezing of gait. Frontiers in neurology 20110101
Molecular level interactions of S100A13 with amlexanox: inhibitor for formation of the multiprotein complex in the nonclassical pathway of acidic fibroblast growth factor. Biochemistry 20100323
Cromoglycate drugs suppress eicosanoid generation in U937 cells by promoting the release of Anx-A1. Biochemical pharmacology 20090615
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. Journal of translational medicine 20090101
A clinical evaluation of amlexanox oral adhesive pellicles in the treatment of recurrent aphthous stomatitis and comparison with amlexanox oral tablets: a randomized, placebo controlled, blinded, multicenter clinical trial. Trials 20090101
PDE4 inhibitors: current status. British journal of pharmacology 20081001
[Local Treatment of stomatitis aphthosa]. Medizinische Monatsschrift fur Pharmazeuten 20080901
Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. Clinical ophthalmology (Auckland, N.Z.) 20080901
Synergistic Ca2+ and Cu2+ requirements of the FGF1-S100A13 interaction measured by quartz crystal microbalance: an initial step in amlexanox-reversible non-classical release of FGF1. Neurochemistry international 20080501
Review of over-the-counter treatments for aphthous ulceration and results from use of a dissolving oral patch containing glycyrrhiza complex herbal extract. The journal of contemporary dental practice 20080301
Effectiveness of two oral pastes for the treatment of recurrent aphthous stomatitis. Oral diseases 20070901
Mucocutaneous lesions of Behcet's disease. Yonsei medical journal 20070831
An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20061001
Evidence for serum-deprivation-induced co-release of FGF-1 and S100A13 from astrocytes. Neurochemistry international 20060801
A late cutaneous response in actively sensitized rats: a new method for evaluating the efficacy of antiallergic drugs. Journal of pharmacological sciences 20060801
Voltage-dependent N-type Ca2+ channel activity regulates the interaction between FGF-1 and S100A13 for stress-induced non-vesicular release. Cellular and molecular neurobiology 20060501
The efficacy of amlexanox OraDisc on the prevention of recurrent minor aphthous ulceration. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20060201
Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Mediators of inflammation 20060101
Molecular mechanism of inhibition of nonclassical FGF-1 export. Biochemistry 20051129
A comparative study of the efficacy of Aphtheal in the management of recurrent minor aphthous ulceration. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20050801
Prediction of genotoxicity of chemical compounds by statistical learning methods. Chemical research in toxicology 20050601
Amlexanox for the treatment of recurrent aphthous ulcers. Clinical drug investigation 20050101
Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. The Biochemical journal 20030901
Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochemical and biophysical research communications 20020412
Selecting topical and systemic agents for recurrent aphthous stomatitis. Cutis 20010901
The precursor but not the mature form of IL1alpha blocks the release of FGF1 in response to heat shock. The Journal of biological chemistry 20010216
Treatment strategies for recurrent oral aphthous ulcers. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010101
The comparative release of FGF1 by hypoxia and temperature stress. Growth factors (Chur, Switzerland) 20010101
Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase. International archives of allergy and applied immunology 19870101
Properties